Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia prior to initiation with aripiprazole treatment and after three months of taking the antipsychotic medication aripiprazole.
| Condition | Intervention |
|---|---|
|
Schizophrenia Sensory Gating |
Drug: Aripiprzole |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole |
- MEG/EEG and MRI data will be compared with the results of a neuropsych battery and symptom rating scales prior to initiation with aripiprazole and after subject has been on a stable dose of aripiprazole for three month. [ Time Frame: MEG/EEG will be repeated after a min. of three months on a stable dose of Aripiprazole ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | August 2003 |
| Estimated Study Completion Date: | September 2008 |
-
Drug: Aripiprzole
Dosage form, dosage, frequency and duration:
Aripiprazole 5-30 mg tabs po qday x 3 months
Problems with attention and perception are core features of schizophrenia and are hypothesized to result from defects in the filtering or gating of sensory input. Examination of this requires neuroimaging techniques with high temporal resolution. High-density EEG and MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory gating. In a number of recent studies patient treated with novel antipsychotics have been shown to have P50 gating ratios resembling those of normal controls rather than that of schizophrenia subjects treatment with conventional antipsychotics. To date, there is no literature on the effects of aripiprzole on sensory gating. Subjects who meet all inclusion criteria will receive a clinical interview, an MRI, MEG, and neuropsychological testing before starting treatment with aripiprazole and again 3 months later to determine if patients with schizophrenia who are treated with aripiprazole will demonstrate a sensory gating ratio similar to normal controls, indicating no deficit in sensory gating
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patient Population
- Diagnosis of Schizophrenia as determine by the Structured Clinical Interview for DSM-IV
- no comorbid diagnosis of PTSD
- continuous treatment with a conventional antipsychotic, risperidone or olanzapine for at least 3 months
- absence of psychiatric hospitalization for at least 3 month
- no history of drug dependency in their lifetime
- no history of alcohol or other substance abuse in the 6 months prior to entry into the study
- no history of head injury with loss of consciousness for more than 5 minutes
- no history of seizure disorder
- no mood stabilizing agents
- between 18-65 and
- able to sign informed consent
Normal Controls
- Matched in age and gender to patient population
- No history of psychiatric dysfunction or alcohol or other substance dependence in their lifetime as determine by the SCID
- No history of alcohol or other substance abuse in the previous 6 months
- No family history of psychotic disorder in first degree relatives as assessed by the FH-RDC diagnostic interview
- No history of head injury with loss of consciousness for more than 5 minutes
- No history of seizure disorder
- Between 18-65
- Able to sign informed consent
Exclusion Criteria:
Subjects will be excluded from participating in this study if they:
- Require treatment with a mood stabilizer
- Have had an inpatient hospitalization in the past 3 months\
- Have a history of a neurological disorder
- Have any other axis I diagnosis besides schizophrenia
Contacts and Locations| Contact: Billy Jimenez | (505) 265-1711 ext 5117 | billy.jiminez@va.gov |
| Contact: Robin R. Douglas, MA, CCRC | (505) 265-1711 ext 5528 | robin.douglas@med.va.gov |
| United States, New Mexico | |
| New Mexico VA Healthcare System | Recruiting |
| Albuquerque, New Mexico, United States, 87108 | |
| Contact: Billy Jimenez 505-265-1711 ext 5117 billy.jimenez@va.gov | |
| Contact: Robin R. Douglas, MA, CCRC (505) 265-1711 ext 5528 robin.douglas@med.va.gov | |
| Principal Investigator: Jose M Canive, MD | |
| Principal Investigator: | Jose M Canive, MD | New Mexico VA Healthcare System / BRINM |
More Information
Additional Information:
No publications provided
| Responsible Party: | Jose M. Canive, MD, New Mexico VA Healthcare System |
| ClinicalTrials.gov Identifier: | NCT00567099 History of Changes |
| Other Study ID Numbers: | 0059, BRINM #150 |
| Study First Received: | December 3, 2007 |
| Last Updated: | May 24, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by New Mexico VA Healthcare System:
|
Psychiatry Antipsychotic Psychopharmacology Clinical Trial Open Label |
Schizophrenia Sensory Gating Attention Memory |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Aripiprazole Antipsychotic Agents Tranquilizing Agents |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 19, 2013